A Study for Japanese Participants With Rheumatoid Arthritis (RA)

Multiple-Dose, Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LY2127399 in Japanese Patients With Rheumatoid Arthritis Treated With Methotrexate

This study will evaluate the safety and tolerability of multiple doses of LY2127399 (tabalumab) in Japanese participants with RA. The study consists of a 20-week treatment period. All participants will be followed for up to 12 weeks after the last study drug administration.

Inclusion Criteria:

• Have given written informed consent
• Women must not be pregnant, breastfeeding or be at risk to become pregnant during study participation
• Diagnosis of RA
• Active RA
• Current, regular use of Methotrexate, at a stable dose
• Body weight between 40 and 105 kilograms (kg), inclusive

Exclusion Criteria:

• Use of excluded medications (reviewed by study doctor)
• Have medical findings which, in the opinion of the study doctor, put participant at an unacceptable risk for participation in the study
• Have had recent or ongoing infection which, in the opinion of the study doctor put participant at an unacceptable risk for participation
• Evidence of tuberculosis
• Have systemic inflammatory condition other than RA